Development of contraceptive vaginal rings for fertility regulation of women

International Medical Journal

Volumn 10, Issue 2, 2003, Pages 119-126

  Sarkar, Narendra Nath ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Contraceptive; Oestrogen; Postpartum; Progestogen; Silicone polymer; Vaginal device

Indexed keywords

CHLORMADINONE ACETATE; ELCOMETRINE; ESTRADIOL; ETHINYLESTRADIOL; ETONOGESTREL; GESTRINONE; LEVONORGESTREL; NORETHISTERONE ACETATE; NORGESTREL; PROGESTERONE;

ACNE; CONTRACEPTION; DEPRESSION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FEMALE; FEMALE FERTILITY; HEADACHE; HUMAN; MENSTRUATION DISORDER; NAUSEA; NERVOUSNESS; OVULATION INHIBITION; REVIEW; SIDE EFFECT; VAGINA RING;

EID: 0041309876     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Green blatt RB. The physiologic effectiveness of progesterone vaginal suppositories. J Clin Endocrinol Metab 1954; 14: 1564-66.
2. Southam AL. A comparative study of the effect of progestational agents in human menstrual abnormalities. Ann NY Acad Sci 1958; 17: 666-76.
3. Mishell DRjr, Talas M, Parlow AF, Moyer DL. Contraception by means of a Silastic vaginal ring impregnated with medroxy progesterone acetate. Am J Obstet Gynaecol 1970; 107: 100-7.
4. Mishell DRjr, Lumkin ME. Contraceptive effect of varying dosages of progestogen in Silastic vaginal ring. Fertil Steril 1970; 21: 99-103.
5. Mishell DRjr. Intravaginal ring for contraceptive use: an editorial comments. Contraception 1975; 12: 249-51.
6. Henzel MR, Mishell DRjr, Velasquez JG, Leitch WE. Basic studies for prolonged progestogen administration by vaginal devices. Am J Obstet Gynaecol 1973; 117: 101-6.
7. Victor A, Edquist LE, Linberg P, Elamsson K, Johansson EDB. Peripheral plasma levels of d-norgestrel in women after oral administration of d-norgestrel and when using intravaginal rings impregnated with dl-norgestrel. Contraception 1975; 12: 261-78.
8. Burton FG, Skiens WE, Gordon NR, Veal JT, Kalkwarf DR, Duncan GW. Fabrication and testing of vaginal contraceptive devices designed for release of pre-specified dose levels of steroids. Contraception 1978; 17: 221-30.
9. Sarkar NN. Bioavailability of contraceptive steroids. Ph. D Thesis, AIIMS, New Delhi, 1980.
10. Victor A, Johansson EDB. Plasma levels of d-norgestrel and ovarian function in women using intravaginal rings impregnated with dl-norgestrel for several cycles. Contraception 1976; 14: 215-26.
11. Akinla O, Lahteenmaki P, Jackanicz TM. Intravaginal contraception with the synthetic progestin R2323. Contraception 1976; 14: 671-8.
12. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multi-centre study of efficacy and safety of a continuous, low-dose, oestradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynaecol 1996; 174: 85-92.
13. Roumen F, Dieben T. Clinical acceptability of an ethylene-vinyl-acetate non-medicated vaginal ring. Contraception 1999; 59: 59-62.
14. Timmer C, Mulders T. Pharmacokinetics of etonorgestrel and ethynylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233-42.
15. Mishell DRjr, Lumkin ME, Stone S. Inhibition of ovulation with cyclic use of progestogen impregnated intravaginal devices. Am J Obstet Gynaecol 1972; 113: 927-32.
16. Thiery M, Vandekerckhove D, Dhont M, Vermeulen A, Decoster JM. The medroxy progesterone acetate intravaginal Silastic ring as a contraceptive device. Contraception 1976; 13: 605-15.
17. Viinikka L, Victor A, Janne O, Raynaud JP. The plasma concentration of a synthetic progestin, R2323 released from polysilastic vaginal rings Contraception 1975; 12: 309-16.
18. Johansson EDB, Luukkainen T, Vartiainen E, Victor A. The effect of progestin R 2323 released from vaginal rings on ovarian function. Contraception 1975; 12: 299-308.
19. Mishell DRjr, Lumkin M, Jackanicz T. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel. Contraception 1975; 12: 253-60.
20. Burton FG, Skiens WE, Duncan GW. Low level, progesterone releasing vaginal contraceptive device. Contraception 1979; 19: 507-16.
21. Landgren BM, Johanisson E, Masironi B, Diczfalusy E. Pharmacokinetic and pharmacodynamic effects of small dose of norethisterone released from vaginal rings continuously during 90 days. Contraception 1979; 19: 253-71.
22. Diaz S, Jackanicz TM, Herreros C, Juez G, Peralta O, Miranda P, et al. Fertility regulation in nursing women: VIII. Progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring. Contraception 1985; 32: 603-22.
23. Sivin I, Diaz S, Croxatto HB, Miranda P, Shaaban M, Sayed EH, et al. Contraceptives for lactating women: a comparative trial of progesterone-releasing vaginal ring and the copper T 380 A IUD. Contraception 1997; 55: 225-32.
24. Chen JH, Wu SC, Shao WG, Zou MH, Hu J, Cong L, et al. The contraceptive trial of T-Cu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception 1998; 57: 371-9.
25. Massai R, Miranda P, Valdes P, Lavin P, Zepeda A, Casado ME. Pre-registration study on the safety and contraceptive efficacy of a progesterone releasing vaginal rings in Chilean nursing women. Contraception 1999; 60: 9-14.
26. Massai R, Diaz S, Jackanicz T, Croxatto HB. Vaginal rings for contraception in lactating women. Steroids 2000; 65: 703-7.
27. R: a progestin with a unique pharmacological profile. Steroids 2000; 65: 629-36.
28. R. Contraception 2001; 63: 257-61.
29. Alvarez F, Brache V, Jackanicz T, Faundes A. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception 1992; 46: 387-98.
30. R subdermal implants. Contraception 2000; 61: 199-204.
31. Brache V, Alvarez F, Faundes A, Jackanicz T, Mishell DRjr, Lahteenmaki P. Progesterone-only contraceptive rings. Steroids 2000; 65: 687-91.
32. Stanczyk FZ, Hiroi M, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DRjr. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. Contraception 1975; 12: 279-98.
33. Victor A, Johansson EDB. Contraceptive rings: self-administered treatment governed by bleeding. Contraception 1977; 16: 137-47.
34. Xiao BL, Zhang XL, Feng DD. Pharmacokinetic and pharmacodynamic studies of vaginal rings. Contraception 1985; 32: 455-71.
35. Gao J, Sun HZ, Song GY, Ma LY. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Fertil Steril 1986; 46: 626-30.
36. Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall GL, Wyss R, et al. Micro-dose intravaginal levonorgestrel contraception: a multi-centre clinical trial. I. Contraceptive efficacy and side effects. WHO task force on long-acting systemic agents for fertility regulation. Contraception 1990; 41: 105-24.
37. Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall GL, Wyss R, et al. Micro-dose intravaginal levonorgestrel contraception: a multi-centre clinical trial. III. The relationship between pregnancy rate and body weight. WHO task force on long-acting systemic agents for fertility regulation. Contraception 1990; 41: 143-50.
38. Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall GL, Wyss R, et al. Micro-dose intravaginal levonorgestrel contraception: a multi-centre clinical trial. II. Expulsions and removals: WHO task force on long-acting systemic agents for fertility regulation. Contraception 1990; 41: 125-41.
39. Landgren BM, Aedo AR, Johannisson E, Cekan SZ. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms / 24 h when used alone or in combination with transdermal systems releasing oestradiol. Contraception 1994; 50: 87-100.
40. Victor A, Nash HA, Jackanicz TM, Johansson EDB. Collagen bands: a new vaginal delivery system for contraceptive steroids. Contraception 1977; 16: 125-35.
41. Toivonen J, Lahteenmaki P, Luukkainen T. Pituitary and gonadal function during the use of norgestrel oestradiol vaginal rings. Contraception 1978; 18: 201-11.
42. Mishell DRjr, Moore DE, Roy S, Brenner PF, Page MA. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of oestradiol and d-norgestrel. Am J Obstet Gynaecol 1978; 130: 55-62.
43. Toivonen J, Lahteenmaki P, Luukkainen T. Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and oestradiol. Contraception 1979; 20: 11-18.
44. Bergink EW, Hamburger AD, DeJaper E, van der Vies J. Binding of a contraceptive progestogen org-2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J Steroid Biochem 1981; 14: 175-83.
45. Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethynylestradiol releasing from different types of contraceptive vaginal rings. Contraception 1990; 42: 629-42.
46. DeLeede LGJ, Govers CPM, deNijs S. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids. Contraception 1986; 34: 589-602.
47. Roumen F, Dieben T, Assendorp R, Bouckaert P. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990; 42: 201-7.
48. Apter D, Cacciatore B, Stenman UH, Alapiessa U, Assendorp R. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethynylestradiol. Contraception 1990; 42: 285-95.
49. Olsson S-E, Odlind V, Johansson E. Clinical results with subcutaneous implants containing 3-keto-desogestrel. Contraception 1990; 42: 1-11.
50. Olsson S-E, Odlind V. Contraception with a vaginal ring releasing 3-keto-desogestrel and ethynylestradiol. Contraception 1990; 42: 563-72.
51. Mulders TM, Dieben TO. Use of novel combined contraceptive vaginal ring, NuvaRing for ovulation inhibition. Fertil Steril 2001; 75: 865-70.
52. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethynylestradiol. Hum Reprod 2001; 16: 469-75.
53. Victor A, Lithell H, Salinus I, Vessby B. Pharmacokinetics of a contraceptive vaginal ring releasing norethindrone and oestradiol: ovarian function, bleeding control and lipoprotein patterns. Ups J Med Sci 1984; 89: 179-88.
54. Ballagh SA, Mishell DRjr, Lacarra M, Shoupe D, Jackanicz TM, Eggena P. A contraceptive vaginal ring releasing norethindrone acetate and ethynylestradiol. Contraception 1994; 50: 517-33.
55. Ballagh SA, Mishell DRjr, Jackanicz TM, Lacarra M, Eggena P. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethynylestradiol. Contraception 1994; 50: 535-49.
56. Weisberg E, Fraser IS, Mishell DRjr, Lacarra M, Bardin CW. The acceptability of a combined oestrogen / progestogen contraceptive vaginal ring. Contraception 1995; 51: 39-44.
57. Weisberg E, Fraser IS, Lacarra M, Mishell DRjr, Jackanicz T. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. Contraception 1997; 56: 233-9.
58. Weisberg E, Fraser IS, Lacarra M, Mishell DRjr, Alvarez F, Brache V, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 1999; 59: 311-8.
59. Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DRjr. Radioimmunoassay of serum medroxy progesterone acetate (provera) in women following oral and intravaginal administration. Steroids 1975; 26: 373-86.
60. Victor A, Johansson EDB. Pharmacokinetic observations on medroxy progesterone acetate administered orally and intravaginally. Contraception 1976; 14: 319-29.
61. Massai MR, Diaz S, Quinteres E, Reyes MV, Herreros C, Zeped A, et al. Contraceptive efficacy and clinical performance of nestorone implants in postpartum women. Contraception 2001; 64: 369-76.
62. Laurikka RM, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethynylestradiol and progestin ST-1435: bleeding control serum steroid concentration, serum lipids and serum chemistry. Contraception 1990; 42: 111-20.
63. Nae G, Salvatierra A, Heikinheimo O, Maturana X, Croxatto HB. Pharmacokinetics and bioavailability of ST-1435 administered by different routes. Contraception 1993; 48: 548-56.
64. Mishell DRjr, Roy S, Moore DE, Brenner PF, Page MA, Gentzschein E, et al. Clinical performance and endocrine profiles with contraceptive vaginal rings containing d-norgestrel. Contraception 1977; 16: 625-29.
65. Jackson R, Newton JR. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel. Contraception 1989; 39: 653-64.
66. Jackson R, Newton JR. The in vivo release characteristics of a multicompartment vaginal ring releasing 3-keto-desogestrel. Contraception 1989; 40: 615-21.
67. Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38: 181-206.
68. Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall GL, Wyss R, et al. Micro-dose intravaginal levonorgestrel contraception: a multi-centre clinical trial. IV. Bleeding patterns. WHO task force on long-acting systemic agents for fertility regulation. Contraception 1990; 41: 151-67.
69. WHO task force on long-acting systemic agents for fertility regulation. Menstrual blood loss with use of a vaginal ring releasing 20 micrograms levonorgestrel per day. Contraception 1993; 47: 455-68.
70. Fraser IS, Weisberg E, Minehan E, Johansson EDB. A detailed analysis of menstrual blood loss in women using norplant and nestorone progesterone only contraceptive implants or vaginal rings. Contraception 2000; 61: 241-51.
71. Bjarnadottir RI, Tuppurainen M, Killick SR. Contraceptive vaginal ring and oral levonorgestrel / ethynylestradiol. Am J Obstet Gynaecol 2002; 186: 389-95.
72. Weisberg E, Fraser IS, Baker J, Archer D, Landgren BM, Killick S, et al. A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 2000; 62: 83-9.
73. Roumen FJ, Boon ME, van-Velzen D, Dieben TO, Coelingh-Bennink HJ. The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring. Hum Reprod 1996; 11: 2443-8.
74. Fraser IS, Lacarra M, Mishell DRjr, Alvarez F, Brache V, Lahteenmaki P, et al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 2000; 61: 131-8.
75. Davies GC, Feng LX, Newton JR, Dieben TO, Coelingh-Bennink HJ. The effect of combined contraceptive vaginal ring releasing ethynylestradiol and 3-keto-desogestrel on vaginal flora. Contraception 1992; 45: 511-18.
76. Roy S, Mishell DRjr, Gray G, Dozono-Takano R, Brenner PF, Fide I, et al. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Am J Obstet Gynaecol 1980; 136: 920-31.
77. Sivin I, Mishell DRjr, Victor A, Diaz S, Alvarez F, Nielsen NC, et al. A multi-centre study of levonorgestrel-oestradiol contraceptive vaginal ring. II. Subjective and objective measures of effects. An international contraceptive trial. Contraception 1981; 24: 359-76.
78. Elder MG, Lawson JP, Elstein M, Nuttall ID. The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort. Contraception 1991; 43: 129-37.
79. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynaecol 2002; 100: 585-93.